Explore

Companies

Drugs

/

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Cardiovascular/Ischemic Stroke

Ischemic Stroke

102

Pipeline Programs↗

285

Active Trials↗

101

Companies Involved↗

Ischemic stroke is a highly competitive landscape with 102 programs across 101 companies. The most active players are Shin Poong Pharmaceutical Co. Ltd., Shaanxi Micot Pharmaceutical Technology Co., Ltd., Hopstem Biotechnology Inc.. 25 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

82/100

Pipeline Velocity

97/100

Mech. Concentration

8/100

Completion Rate

78/100

Attrition Rate

9/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved

Phase 3

Phase 2

Phase 1

Preclinical

Key Players

Top Companies

Shin Poong Pharmaceutical Co. Ltd.

1 program

Shaanxi Micot Pharmaceutical Technology Co., Ltd.

1 program

Hopstem Biotechnology Inc.

1 program

POLYSAN Scientific & Technological Pharmaceutical Company

1 program

Astellas

1 program

Pipeline

Programs by Phase

Preclinical52

Intra-Arterial Administration of Tenecteplase

Hui-Sheng Chen

Magnesium

Spherium Biomed

Revelisa

Federal Center of Cerebrovascular Pathology and Stroke, Russian Federation Ministry of Health

Acetaminophen

Kenvue Brands

Intra-Arterial Cocktail Therapy

Hui-Sheng Chen

Phase 14

Ino

University of Colorado, Denver

Hnpc01

Hopstem Biotechnology Inc.

Magnesium Sulfate

Fresenius Kabi USA, LLC

SNE-101

S&Ebio Co. Ltd.

Phase 221

ALT001

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Tacrolimus

Veloxis Pharmaceuticals

Intra-Arterial Tenecteplase Administration

University of Pennsylvania

TS23

Translational Sciences, Inc.

Dornase Alfa

Roche

Phase 325

Tirofiban Hydrochloride

Medicure

Edaravone Dexborneol

Simcere Pharmaceutical Co., Ltd

Butylphthalide

Peking Union Medical College Hospital

Tegoprazan

Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.

Alteplase or Tenecteplase

Chinese University of Hong Kong

Approved

No programs

Analysis

Modality Breakdown

83%

Small molecule

76 of 92 classified programs — the dominant modality here.

Small molecule leads; the ring shows all 92 classified programs, each share of the total. Modality classified for 98% of 102 pipeline programs.

Analysis

Trial Status

704

clinical trials

Completed244 · 35%

Recruiting161 · 23%

Unknown status106 · 15%

Not yet recruiting100 · 14%

Terminated44 · 6%

Active, not recruiting20 · 3%

Other29 · 4%

Clinical Trials

Trial Activity

704 trials

Efficacy and Safety of Interleukin-6 Receptor Inhibitor Combined With Endovascular Treatment in Patients With Acute Posterior Circulation Large Vessel Occlusion Stroke: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial-3

Recruiting·CCapital Medical University·Phase 3·NCT07509645·348 enrolled

A Multicenter, Double-blind, Placebo-controlled, Randomized Clinical Trial of Probucol in Reducing the Risk of Recurrent Stroke in Patients With Symptomatic Intracranial and Extracranial Large-artery Stenosis

Recruiting·FFirst Affiliated Hospital of Wannan Medical College·Phase 3·NCT06225752·5,452 enrolled

Connectomic Alterations Following Acute Ischemic Stroke in the Middle Cerebral Artery Territory: A Pilot Study of Prognostic Value and Structural Disruption

Recruiting·NNorthwell Health·Preclinical·NCT07584681·10 enrolled

Sevoflurane vs. Propofol for General Anesthesia in Patients With Acute Ischemic Stroke Treated With Endovascular Therapy (SAVE Trial)

Recruiting·FFundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau·Phase 3·NCT07902791·314 enrolled

FORWARD: Functional Outcomes in Real-World Treatment And Revascularization of Non-dominant and Distal M2 Occlusions

Recruiting·PPenumbra Inc.·N/A·NCT07749170·250 enrolled

Albumin for Patients With Acute Large Vessel Occlusive Stroke Undergoing Endovascular Therapy -2

Recruiting·CCapital Medical University·Phase 3·NCT07263308·1,192 enrolled

Evaluating the Clinical Integration of NRICM301, a Food-Grade Innovative Formula, in Acute Ischemic Stroke Care: Safety Observation and Feasibility Assessment

Recruiting·EEn Chu Kong Hospital·Preclinical·NCT07900503·45 enrolled

Rapid Local Ischemic Postconditioning Following Successful Recanalization After Endovascular Thrombectomy in Large Ischemic Core Stroke

Recruiting·SShanghai Jiao Tong University Affiliated Sixth People's Hospital·Preclinical·NCT07598799·448 enrolled

A Clinical Trial to Evaluate the Safety and Efficacy of Allogeneic Human Bone Marrow Mesenchymal Stem Cell (CG-BM1) Injection in the Treatment of Ischemic Stroke

Recruiting·GGuangZhou Cellgenes Biotechnology Co., Ltd.·Preclinical·NCT07896941·87 enrolled

Early Closure of Left Atrial Appendage for Patients With Atrial Fibrillation and Ischemic StrokE Despite Anticoagulation Therapy

Recruiting·IInsel Gruppe AG, University Hospital Bern·Preclinical·NCT05976685·482 enrolled

TENACITY - A Phase III, Prospective, Randomized, Open-label, Blinded Endpoint Assessment (PROBE) to Assess Efficacy and Safety of i.v. Tenecteplase vs Standard of Care in Patients With Acute Ischemic Stroke (Including Wake-up Stroke), Last Known Well >4.5 h With Imaging Evidence of Salvageable Ischemic Tissue

Recruiting· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 3·NCT07361302·1,325 enrolled

Stroke-induced Myocardial Dysfunction: Role of GDF-15 (SMOG-15) Clinical Work Package

Recruiting·CCentre Hospitalier Universitaire Dijon·N/A·NCT05683873·130 enrolled

An Open-Label, Single-Arm, Exploratory Study to Evaluate Intracranial Arterial Recanalization With Multiple Doses of LT3001 Drug Product in Participants With Acute Ischemic Stroke (AIS)

Recruiting·LLumosa Therapeutics Co., Ltd.·Phase 2·NCT07890298·10 enrolled

Tenecteplase or Reteplase as Bridging Thrombolysis Before Thrombectomy in Acute Ischemic Cerebrovascular Events (TRACE-BRIDGE): A Multicenter, Randomized, Open-Label, Three-Arm, Blinded-Endpoint Phase III Trial

Recruiting·—·Phase 3·NCT07748039·1,440 enrolled

A Multicentre, Prospective, Randomized, Open Label, Blinded-endpoint Trial to Optimize the Use of Intravenous Tenecteplase in Participants With Acute Ischemic Stroke (ACT-GLOBAL THROMBOLYSIS (ACT WHEN-001) Within A Multi-faCtorial, mulTi-arm, Multi-staGe, Randomised, gLOBal Adaptive pLatform Trial for Stroke (ACT-GLOBAL) NCT06352632

Recruiting·UUniversity of Calgary·Phase 3·NCT06320431·4,000 enrolled

Page 1 of 47

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)